Teva gets FDA nod for breast cancer treatment

The pharmaceutical company reported the commercial launch of generic Arimidex.

Generic pharmaceuticals giant Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) said that the US Food and Drug Administration (FDA) has approved Teva's generic version of AstraZeneca's breast cancer drug Arimidex.

Based on IMS sales data, the branded drug has annual sales of about $916.8 million.

Teva said that it began its commercial launch of Anastrozole tablets 1 mg, the company’s generic version of AstraZeneca’s Arimidex. The product is used to treat certain forms of breast cancer in postmenopausal women.

Published by Globes [online], Israel business news - - on June 29, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס Capital  Markets Conference 2017